164 related articles for article (PubMed ID: 31764847)
21. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
Rassy E; Flippot R; Albiges L
Ther Adv Med Oncol; 2020; 12():1758835920907504. PubMed ID: 32215057
[TBL] [Abstract][Full Text] [Related]
24. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
25. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Calvo E; Ravaud A; Bellmunt J
Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
27. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Massari F
Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1225-1232. PubMed ID: 34167420
[TBL] [Abstract][Full Text] [Related]
28. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
29. Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors.
Miyake H; Harada K; Inoue TA; Fujisawa M
Med Oncol; 2014 Sep; 31(9):190. PubMed ID: 25146670
[TBL] [Abstract][Full Text] [Related]
30. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.
Shah RR; Morganroth J; Shah DR
Drug Saf; 2013 Jul; 36(7):491-503. PubMed ID: 23620168
[TBL] [Abstract][Full Text] [Related]
31. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs.
Beuselinck B; Jean-Baptiste J; Couchy G; Job S; De Reynies A; Wolter P; Théodore C; Gravis G; Rousseau B; Albiges L; Joniau S; Verkarre V; Lerut E; Patard JJ; Schöffski P; Méjean A; Elaidi R; Oudard S; Zucman-Rossi J
Br J Cancer; 2015 Nov; 113(9):1313-22. PubMed ID: 26528707
[TBL] [Abstract][Full Text] [Related]
32. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
33. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
[TBL] [Abstract][Full Text] [Related]
34. A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma.
Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
Asia Pac J Clin Oncol; 2016 Jun; 12(2):174-80. PubMed ID: 26997520
[TBL] [Abstract][Full Text] [Related]
35. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
36. Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma.
Corona-Rodarte E; Olivas-Martínez A; Remolina-Bonilla YA; Domínguez-Cherit JG; Lam ET; Bourlon MT
Int J Dermatol; 2021 Oct; 60(10):1242-1247. PubMed ID: 33871070
[TBL] [Abstract][Full Text] [Related]
37. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
[TBL] [Abstract][Full Text] [Related]
39. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
40. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
Bersanelli M; Iacovelli R; Buti S; Houede N; Laguerre B; Procopio G; Lheureux S; Fischer R; Negrier S; Ravaud A; Oudard S; Escudier B; Albiges L; Porta C
Eur Urol Oncol; 2021 Apr; 4(2):274-281. PubMed ID: 31331862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]